H.C. Wainwright lowered the firm’s price target on Century Therapeutics to $11 from $13 and keeps a Buy rating on the shares post the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Century Therapeutics price target lowered to $9 from $10 at Piper Sandler
- Century Therapeutics Executes Strategic Acquisition and Equity Sales
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Questions or Comments about the article? Write to editor@tipranks.com